Arzerra

Arzerra (ofatumumab) is approved for patients with chronic lymphocytic leukemia (CLL) whose cancer is no longer being controlled by other forms of chemotherapy. The product was approved under the FDA's accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs.